Literature DB >> 10427515

[Disseminated ischemic necrosis and livedo racemosa in a chronic dialysis patient with calciphylaxis].

A Henschel1, L Dannenberg, U Göbel, A Ott, U Schultz-Ehrenburg.   

Abstract

Calciphylaxis occurred in a 40-year old female patient with end-stage renal failure. The patient developed livedo racemosa ("livedo reticularis") with painful skin necrosis and ulcers involving multiple areas of the hip and legs after 22 years of hemodialysis. X-ray-examinations revealed calcinosis of peripheral arteries, especially of the pelvis, thigh and hands, while histological examinations showed a fibrosis and calcinosis of small subcutaneous arteries. A generalized cutaneous microangiopathy could be demonstrated by transcutaneous oxygen pressure measurements. Laboratory data showed a moderate secondary hyperparathyroidism with mild elevation of calcium-phosphate product. In addition to the hemodialysis an attempt was made to improve the microcirculation by vasoactive drugs. The clinical course was characterized by slow healing of the ulcers and occurrence of new areas of cutaneous necrosis. Calciphylaxis is a rare late complication in patients with advanced, often end-stage renal failure. It has characteristic histopathological features and is frequently, but not always, associated with a disturbed calcium and phosphorus metabolism and mildly elevated levels of parathyroid hormone. Calciphylaxis is classified as a special type of metastatic calcinosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427515     DOI: 10.1007/s001050050939

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  2 in total

1.  [Painful ulcerating livid erythema in a 58-year old patient].

Authors:  D Hoeft; U Hillen; M Goos; J Dissemond
Journal:  Hautarzt       Date:  2004-06       Impact factor: 0.751

Review 2.  The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.

Authors:  Markus Kraemer; Dieter Linden; Peter Berlit
Journal:  J Neurol       Date:  2005-08-26       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.